Reports to: Chief Medical Officer (CMO)

The Company

NodThera is a clinical-stage biotechnology company pioneering a paradigm shift in the treatment of chronic inflammatory diseases. Our focus is on developing a new class of potent, highly selective, and brain-penetrant NLRP3 inflammasome inhibitors. We have three therapeutic areas of focus- cardiometabolism, neuroinflammation, and peripheral inflammation. Of these, cardiometabolism is of
highest priority as we advance rapidly through phase 2 into phase 3.

Unlike traditional approaches that block individual downstream cytokines, NodThera’s small molecules address the upstream catalyst of inflammation. With our lead candidate, NT-0796, we are uniquely positioned to address the “missing link” in cardiometabolic health: hypothalamic and systemic inflammation. Our recent data demonstrates that by resetting the body’s metabolic set-point and reducing markers like hsCRP, we can deliver cardiovascular risk reduction that rivals other mechanisms with the additional potential of metabolic benefits.

The Role

We are looking to hire a TA Head for CardioMetabolism, to join our team to drive our end-to-end clinical development strategy—from late-stage translation to registrational trials. This role will report directly to the CMO. In this role, S/he will be the clinical architect and strategic leader for our high profile clinical programs. S/he will join at a pivotal inflection point as we advance our RESOLVE program in cardiometabolism to phase 3.

Key Responsibilities

• Clinical Strategy & Leadership: Refine and execute the global clinical development plan (CDP) for the CardioMetabolic portfolio, ensuring alignment with NodThera’s mission to treat chronic inflammation at its source.
• Trial Oversight: Provide medical and strategic leadership for all clinical trials in cardiometabolism, ensuring high-quality data generation and clinical excellence.
• Trial Design Innovation: Working with our extensive set of experienced advisors you will spearhead innovative approaches in cardiometabolic clinical development in close partnership with regulatory and operational experts.
• Regulatory & Stakeholder Engagement: Act as the primary medical spokesperson for the TA with global regulatory agencies (FDA, EMA), the Board of Directors, and the investment community.
• Thought Leadership: Build and maintain deep relationships with Global Key Opinion Leaders (KOLs) in cardiology, endocrinology, and obesity. Present groundbreaking data at major medical congresses (ACC, AHA, ADA).
• Cross-Functional Collaboration: Partner with Research/Discovery to identify next-generation cardiometabolic targets and with Commercial/BD to shape the market-access strategy for a “best-in-class” oral inhibitor.

Requirements

• MD or MD/PhD with board certification in Cardiology, Endocrinology, or a related field.
• Minimum of 8 years of drug development experience within biotech or pharmaceutical environments, with a proven track record of leading successful Phase 2/3 programs. Experience with cardiovascular outcome trials is essential.
• Expertise in Cardiometabolism: You must understand the evolving landscape of obesity, ASCVD risk reduction, and the role of inflammatory biomarkers (e.g., CRP, IL-1β, IL-6).
• Small Molecule & Immunology Fluency: Experience with immunology, and oral small-molecule development would be desirable.
• Strategic Agility: The ability to pivot between deep scientific “craftsmanship” and high-level corporate strategy.
• Communication: A “master of your craft” who can communicate complex science to diverse audiences—from academic experts to venture capital investors.

Qualified candidates should email resume / CV to Recruiting@Nodthera.com